KRAS Mutant Cancer - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: K89CC122065AEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'KRAS Mutant Cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted KRAS Mutant Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

KRAS Mutant Cancer Understanding

The DelveInsight KRAS Mutant Cancer epidemiology report gives a thorough understanding of the KRAS Mutant Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for KRAS Mutant Cancer in the US, Europe, and Japan. The report covers the detailed information of the KRAS Mutant Cancer epidemiology scenario in seven major countries (US, EU5, and Japan).

KRAS Mutant Cancer Epidemiology Perspective by DelveInsight

The KRAS Mutant Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The KRAS Mutant Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The KRAS Mutant Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

KRAS Mutant Cancer Detailed Epidemiology Segmentation

The KRAS Mutant Cancer epidemiology covered in the report provides historical as well as forecasted KRAS Mutant Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight KRAS Mutant Cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The KRAS Mutant Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The KRAS Mutant Cancer Epidemiology Report and Model provide an overview of the global trends of KRAS Mutant Cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of KRAS Mutant Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of KRAS Mutant Cancer
• The report provides the segmentation of the KRAS Mutant Cancer epidemiology

Report Highlights

• 11-year Forecast of KRAS Mutant Cancer epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of KRAS Mutant Cancer
• Cases of KRAS Mutant Cancer by Mutation Types
• KRAS Mutant Cancer Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to KRAS Mutant Cancer?
• What are the key findings pertaining to the KRAS Mutant Cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of KRAS Mutant Cancer across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of KRAS Mutant Cancer?
• What are the currently available treatments of KRAS Mutant Cancer?

Reasons to buy

The KRAS Mutant Cancer Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global KRAS Mutant Cancer market
• Quantify patient populations in the global KRAS Mutant Cancer market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for KRAS Mutant Cancer therapeutics in each of the markets covered
• Understand the magnitude of KRAS Mutant Cancer population by its epidemiology
• The KRAS Mutant Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF KRAS MUTANT CANCER

3. KRAS MUTANT CANCER: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. KRAS Mutant Cancer Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. KRAS Mutant Cancer Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. KRAS Mutant Cancer Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. KRAS Mutant Cancer Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. KRAS Mutant Cancer Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. KRAS Mutant Cancer Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. KRAS Mutant Cancer Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. KRAS Mutant Cancer Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. KRAS Mutant Cancer Treatment and Management
6.2. KRAS Mutant Cancer Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: KRAS Mutant Cancer Epidemiology in 7MM (2019-2032)
Table 2: KRAS Mutant Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: KRAS Mutant Cancer Epidemiology in the United States (2019-2032)
Table 4: KRAS Mutant Cancer Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: KRAS Mutant Cancer Epidemiology in Germany (2019-2032)
Table 6: KRAS Mutant Cancer Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: KRAS Mutant Cancer Epidemiology in France (2019-2032)
Table 8: KRAS Mutant Cancer Diagnosed and Treatable Cases in France (2019-2032)
Table 9: KRAS Mutant Cancer Epidemiology in Italy (2019-2032)
Table 10: KRAS Mutant Cancer Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: KRAS Mutant Cancer Epidemiology in Spain (2019-2032)
Table 12: KRAS Mutant Cancer Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: KRAS Mutant Cancer Epidemiology in the United Kingdom (2019-2032)
Table 14: KRAS Mutant Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: KRAS Mutant Cancer Epidemiology in Japan (2019-2032)
Table 16: KRAS Mutant Cancer Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 KRAS Mutant Cancer Epidemiology in 7MM (2019-2032)
Figure 2 KRAS Mutant Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 KRAS Mutant Cancer Epidemiology in the United States (2019-2032)
Figure 4 KRAS Mutant Cancer Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 KRAS Mutant Cancer Epidemiology in Germany (2019-2032)
Figure 6 KRAS Mutant Cancer Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 KRAS Mutant Cancer Epidemiology in France (2019-2032)
Figure 8 KRAS Mutant Cancer Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 KRAS Mutant Cancer Epidemiology in Italy (2019-2032)
Figure 10 KRAS Mutant Cancer Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 KRAS Mutant Cancer Epidemiology in Spain (2019-2032)
Figure 12 KRAS Mutant Cancer Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 KRAS Mutant Cancer Epidemiology in the United Kingdom (2019-2032)
Figure 14 KRAS Mutant Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 KRAS Mutant Cancer Epidemiology in Japan (2019-2032)
Figure 16 KRAS Mutant Cancer Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report